Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research report released on Wednesday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $5.00 price target on shares of Minerva Neurosciences in a research report on Wednesday, February 26th.

Minerva Neurosciences Price Performance

Shares of NERV opened at $1.81 on Wednesday. The company has a market cap of $12.66 million, a P/E ratio of -4.11 and a beta of 0.10. Minerva Neurosciences has a fifty-two week low of $1.42 and a fifty-two week high of $3.69. The firm’s 50 day moving average price is $1.93 and its 200 day moving average price is $2.24.

Minerva Neurosciences (NASDAQ:NERV) last posted its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.49. Research analysts forecast that Minerva Neurosciences will post -0.3 earnings per share for the current year.

Hedge Funds Weigh In On Minerva Neurosciences

A hedge fund recently raised its stake in Minerva Neurosciences stock. Northern Trust Corp increased its holdings in shares of Minerva Neurosciences, Inc. (NASDAQ:NERV) by 60.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 36,878 shares of the biopharmaceutical company’s stock after purchasing an additional 13,829 shares during the period. Northern Trust Corp owned 0.53% of Minerva Neurosciences worth $82,000 as of its most recent SEC filing. 34.56% of the stock is currently owned by hedge funds and other institutional investors.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.